Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
Around 12% of hereditary disease-causing mutations are in-frame nonsense mutations. The expression of genes containing nonsense mutations potentially leads to the production of truncated proteins with residual or virtually no function. However, the translation of transcripts containing premature sto...
Saved in:
Main Author: | Sylwia Michorowska (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
by: Maciej Dabrowski, et al.
Published: (2018) -
Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons
by: Nesrine Benslimane, et al.
Published: (2024) -
ACEing premature codon termination using anticodon-engineered sup-tRNA-based therapy
by: Ting-Yu Lin, et al.
Published: (2022) -
A murine Zic3 transcript with a premature termination codon evades nonsense-mediated decay during axis formation
by: Jehangir N. Ahmed, et al.
Published: (2013) -
Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia
by: Celia Djayet, et al.
Published: (2020)